News Quantified

DMAC – diamedica therapeutics inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

DiaMedica Therapeutics Inc. (NASDAQ: DMAC) had its price target raised by analysts at HC Wainwright from $7.00 to $10.00. They now have a "buy" rating on the stock.

DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2024 Financial Results

Insider Stock Buying Reaches US$9.00m On DiaMedica Therapeutics [Yahoo! Finance]

DiaMedica Therapeutics to Report Fourth Quarter 2024 Financial Results and Provide a Business Update March 18, 2025

DiaMedica Therapeutics Appoints Daniel J. O'Connor to the Board of Directors [Yahoo! Finance]

-5.5%

MISS

3.1%

BEAT

-5.2%

BEAT

Form ARS DiaMedica Therapeutics For: Dec 31

Form DEFA14A DiaMedica Therapeutics

Form DEF 14A DiaMedica Therapeutics For: May 15

Form 10-K DiaMedica Therapeutics For: Dec 31

Form 8-K DiaMedica Therapeutics For: Mar 17

Top News Gainers

6/19 DiaMedica Therapeutics Announces Interim Results from Phase 1b Trial of DM199 in Chronic Kidney Disease Participants 26.7%

10/14 DiaMedica Therapeutics Announces Clearance to Initiate Phase II Clinical Trial of DM199 for Chronic Kidney Disease 17.9%

12/17 DiaMedica Therapeutics Announces First Patient Dosed in REDUX Phase II Clinical Trial of DM199 for the Treatment of Chronic Kidney Disease 16.5%

1/3 Form 8-K DiaMedica Therapeutics For: Dec 27 11.8%

1/15 DiaMedica Therapeutics Inc (NASDAQ: DMAC) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 11.6%

8/19 Form 4 DiaMedica Therapeutics For: Aug 19 Filed by: Kellen Scott 8.6%

12/24 Hedge Funds Have Never Been More Bullish On DiaMedica Therapeutics Inc. (DMAC) [Yahoo! Finance News] 8.2%

11/14 DiaMedica Therapeutics Inc. 2019 Q3 - Results - Earnings Call Presentation [Seeking Alpha] 7.6%

3/26 DiaMedica Therapeutics to Present Research at National Kidney Foundation 2020 Spring Clinical Meetings Live Virtual Conference 7.2%

5/14 DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha] 5.8%

Top News Decliners

8/13 DiaMedica Therapeutics Announces Second Quarter 2019 Financial Results and Provides Business Update -34.7%

11/28 DiaMedica Therapeutics Inc (NASDAQ: DMAC) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -13.7%

3/24 DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] -12.7%

12/13 DiaMedica Therapeutics Inc (NASDAQ: DMAC) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -11.8%

11/13 DiaMedica Therapeutics Announces Third Quarter 2019 Financial Results and Provides Business Update -8.6%

9/3 DiaMedica Therapeutics to Present at the 2019 Dougherty & Co. Institutional Investor Conference -7.4%

1/3 DiaMedica Therapeutics Inc (NASDAQ: DMAC) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -7.2%

7/16 DiaMedica Therapeutics Inc (NASDAQ: DMAC) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -7.0%

9/6 DiaMedica Therapeutics to Present at Lake Street’s 3rd Annual Best Ideas Growth (BIG3) Conference on September 12, 2019 -6.6%

2/11 Form 424B5 DiaMedica Therapeutics -5.8%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day